Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9BPW9

UPID:
DHRS9_HUMAN

ALTERNATIVE NAMES:
3-alpha hydroxysteroid dehydrogenase; NADP-dependent retinol dehydrogenase/reductase; RDH-E2; RDHL; Retinol dehydrogenase 15; Short chain dehydrogenase/reductase family 9C member 4; Short-chain dehydrogenase/reductase retSDR8; Tracheobronchial epithelial cell-specific retinol dehydrogenase

ALTERNATIVE UPACC:
Q9BPW9; B7Z416; D3DPC1; Q5RKX1; Q9NRA9; Q9NRB0

BACKGROUND:
The protein Dehydrogenase/reductase SDR family member 9, with aliases such as RDH-E2 and Short chain dehydrogenase/reductase family 9C member 4, is pivotal in converting key steroids and in retinoic acid synthesis. Its ability to use both NADH and NADPH for the conversion of 3-alpha-tetrahydroprogesterone and 3-alpha-androstanediol to dihydroxyprogesterone, as well as retinaldehyde to retinoic acid, positions it as a significant player in metabolic pathways.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Dehydrogenase/reductase SDR family member 9 offers a promising avenue for the development of novel therapeutic approaches, particularly in disorders related to steroid metabolism and retinoid pathways.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.